376.80
price up icon0.74%   2.78
pre-market  Pre-market:  376.00   -0.80   -0.21%
loading
United Therapeutics Corp stock is traded at $376.80, with a volume of 320.80K. It is up +0.74% in the last 24 hours and up +5.86% over the past month. United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$374.02
Open:
$373.98
24h Volume:
320.80K
Relative Volume:
0.85
Market Cap:
$16.82B
Revenue:
$2.62B
Net Income/Loss:
$1.07B
P/E Ratio:
20.76
EPS:
18.15
Net Cash Flow:
$877.90M
1W Performance:
+7.75%
1M Performance:
+5.86%
6M Performance:
+43.60%
1Y Performance:
+67.89%
1-Day Range:
Value
$371.32
$379.51
1-Week Range:
Value
$343.57
$379.51
52-Week Range:
Value
$208.62
$379.51

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Name
United Therapeutics Corp
Name
Phone
(301) 608-9292
Name
Address
1000 SPRING ST, SILVER SPRING, MD
Name
Employee
1,168
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
UTHR's Discussions on Twitter

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-11-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-12-24 Upgrade Goldman Sell → Neutral
Feb-05-24 Initiated Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Dec-06-22 Initiated UBS Buy
Dec-05-22 Initiated Goldman Sell
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-20-22 Reiterated BofA Securities Underperform
Sep-19-22 Resumed Wedbush Outperform
Feb-11-22 Initiated BTIG Research Neutral
Jul-14-21 Upgrade Argus Hold → Buy
Apr-26-21 Resumed Credit Suisse Outperform
Feb-01-21 Upgrade H.C. Wainwright Neutral → Buy
Sep-14-20 Resumed JP Morgan Overweight
Jun-25-20 Reiterated H.C. Wainwright Neutral
Mar-10-20 Upgrade Jefferies Hold → Buy
Feb-27-20 Upgrade Cowen Market Perform → Outperform
Jan-31-20 Upgrade JP Morgan Neutral → Overweight
Dec-03-19 Initiated BofA/Merrill Underperform
Aug-01-19 Upgrade Jefferies Underperform → Hold
Aug-01-19 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-01-19 Upgrade Credit Suisse Neutral → Outperform
May-17-19 Upgrade UBS Sell → Neutral
May-09-19 Upgrade Credit Suisse Underperform → Neutral
Oct-12-18 Upgrade Standpoint Research Hold → Buy
Aug-08-18 Downgrade Credit Suisse Neutral → Underperform
Apr-03-18 Upgrade Credit Suisse Underperform → Neutral
Feb-22-18 Reiterated Barclays Underweight
Jan-18-18 Resumed Credit Suisse Underperform
Dec-27-17 Reiterated Wedbush Outperform
Apr-27-17 Reiterated Wedbush Outperform
Mar-30-17 Initiated UBS Sell
Mar-16-17 Initiated Credit Suisse Underperform
View All

United Therapeutics Corp Stock (UTHR) Latest News

pulisher
Nov 04, 2024

Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

United Therapeutics Co. (NASDAQ:UTHR) Director Sells $192,081.30 in Stock - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Sandoz Wins $70M In Antitrust Suit Over Hypertension Drug - Law360

Nov 04, 2024
pulisher
Nov 04, 2024

Sandoz's Award Cut to $71 Million in Generic-Remodulin UTC Case - Bloomberg Law

Nov 04, 2024
pulisher
Nov 02, 2024

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024
pulisher
Nov 02, 2024

New York State Teachers Retirement System Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Nov 02, 2024
pulisher
Nov 02, 2024

MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

United Therapeutics (NASDAQ:UTHR) Price Target Raised to $302.00 at The Goldman Sachs Group - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

United Therapeutics Q3 Earnings & Sales Beat Estimates - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

United Therapeutics (NASDAQ:UTHR) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

United Therapeutics stock soars to all-time high of $377.93 - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

United Therapeutics shares rated Neutral by Ladenburg, target lifted on Tyvaso sales strength - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

United Therapeutics shares target raised to $425 by H.C. Wainwright - Investing.com India

Nov 01, 2024
pulisher
Oct 31, 2024

United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by AustralianSuper Pty Ltd - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Beats Expectations By $0.23 EPS - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: United Therapeutics reports robust Q3 growth, eyes future milestones - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

United Therapeutics: Q3 Earnings Snapshot - Milford Mirror

Oct 31, 2024
pulisher
Oct 31, 2024

United Therapeutics Corp Q3 2024 Earnings: Revenue Hits $748.9M, EPS at $6.39, Surpassing Estimates - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

United Therapeutics Corp (UTHR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

United Therapeutics Reports Strong Q3 2024 Results - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

United Therapeutics earnings missed by $0.14, revenue topped estimates - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results - StockTitan

Oct 30, 2024
pulisher
Oct 29, 2024

Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

China Universal Asset Management Co. Ltd. Has $3.07 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

FCG Investment Co Acquires New Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 28, 2024
pulisher
Oct 23, 2024

United Therapeutics (NASDAQ:UTHR) Trading Down 6.8% After Insider Selling - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service - StockTitan

Oct 23, 2024
pulisher
Oct 23, 2024

United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024 - StockTitan

Oct 23, 2024
pulisher
Oct 22, 2024

United Therapeutics CFO sells shares worth $2.45 million By Investing.com - Investing.com Canada

Oct 22, 2024
pulisher
Oct 22, 2024

United Therapeutics CFO sells shares worth $2.45 million - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

James Edgemond Sells 7,782 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

Toth Financial Advisory Corp Has $1.04 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 21, 2024
pulisher
Oct 17, 2024

United Therapeutics (NASDAQ:UTHR) Upgraded to "Strong-Buy" by StockNews.com - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

State Street Corp's Strategic Reduction in United Therapeutics Holdings - GuruFocus.com

Oct 16, 2024
pulisher
Oct 16, 2024

United Therapeutics (NASDAQ:UTHR) Hits New 52-Week HighHere's What Happened - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

United Therapeutics stock soars to all-time high of $366.23 - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

United Therapeutics stock soars to all-time high of $366.23 By Investing.com - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Livforsakringsbolaget Skandia Omsesidigt Sells 20,450 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

United Therapeutics Co. (NASDAQ:UTHR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

United Therapeutics CFO James Edgemond sells $2.37m in stock By Investing.com - Investing.com Australia

Oct 15, 2024
pulisher
Oct 15, 2024

United Therapeutics CFO James Edgemond sells $2.37m in stock - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,773,016.96 in Stock - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Swedbank AB Decreases Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

Inspire Investing LLC Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat

Oct 13, 2024
pulisher
Oct 12, 2024

United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Diversified Trust Co - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

United Therapeutics Co. (NASDAQ:UTHR) Short Interest Update - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

United Therapeutics Corp (UTHR) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Focus - GuruFocus.com

Oct 10, 2024

United Therapeutics Corp Stock (UTHR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.75
price down icon 0.50%
$19.96
price up icon 5.11%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
Cap:     |  Volume (24h):